Alpha 2.0
Login Register
» Articles » PMID: 27722106

Nonresponsiveness to Standard Treatment in Cutaneous Leishmaniasis: A Case Series from Sri Lanka

Overview
Journal Trop Parasitol
Specialty Parasitology
Date 2016 Oct 11
PMID 27722106
Citations 12
Authors
Fathima Wardha Refai
Nayani P Madarasingha
Rohini Fernandopulle
Nadira Karunaweera
Affiliations
Soon will be listed here.
Abstract

Leishmaniasis is caused by parasitic protozoa of the genus . Cutaneous leishmaniasis (CL) is endemic in Sri Lanka with over 3000 cases during the last decade and numbers are increasing. Treatment options available in Sri Lanka for CL include intralesional/intramuscular sodium stibogluconate and cryotherapy. Eight cases of treatment failure with standard therapy are reported from the Dermatology Clinic, Teaching Hospital Anuradhapura. Therapeutic regimes aim for clinical healing, these patients responded poorly to anti-leishmanial therapy, indicating the need for close monitoring, explore alternative treatment options and to investigate for drug resistance in parasites.

Citing Articles

Development of a Highly Sensitive Nested PCR and Its Application for the Diagnosis of Cutaneous Leishmaniasis in Sri Lanka.

De Silva N, De Silva V, Deerasinghe A, Rathnapala U, Itoh M, Takagi H Microorganisms. 2022; 10(5).

PMID: 35630433 PMC: 9145043. DOI: 10.3390/microorganisms10050990.

Treatment failure to sodium stibogluconate in cutaneous leishmaniasis: A challenge to infection control and disease elimination.

Silva H, Liyanage A, Deerasinghe T, Chandrasekara V, Chellappan K, Karunaweera N PLoS One. 2021; 16(10):e0259009.

PMID: 34679130 PMC: 8535432. DOI: 10.1371/journal.pone.0259009.

Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.

Dey N, Senaratne S, Somaratne V, Madarasinghe N, Seneviratne B, Forrester S J Clin Invest. 2021; 131(22).

PMID: 34609968 PMC: 8592550. DOI: 10.1172/JCI142765.

The Leishmania antigen-specific pro-inflammatory response in cutaneous leishmaniasis is linked to disease progression but not to the therapeutic failure of pentavalent antimonials.

Franca M, Guimaraes L, Nascimento M, Rocha P, Carvalho L Microbes Infect. 2021; 23(9-10):104866.

PMID: 34298178 PMC: 8687710. DOI: 10.1016/j.micinf.2021.104866.

First Evidence from Sri Lanka for Subphenotypic Diversity within -Induced Classical Cutaneous Leishmaniasis.

Siriwardana Y, Deepachandi B, Weerasinghe S, Karunaweera N, Udagedara C, Warnasuriya W Biomed Res Int. 2021; 2021:3537968.

PMID: 33575327 PMC: 7861938. DOI: 10.1155/2021/3537968.

References
1.
Navin T, Arana B, Arana F, Berman J, Chajon J . Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992; 165(3):528-34. DOI: 10.1093/infdis/165.3.528. View
2.
Sundar S, Thakur B, Tandon A, Agrawal N, Mishra C, Mahapatra T . Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ. 1994; 308(6924):307. PMC: 2539260. DOI: 10.1136/bmj.308.6924.307. View
3.
Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E . Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis. 1999; 180(2):564-7. DOI: 10.1086/314896. View
4.
Chakravarty J, Sundar S . Drug resistance in leishmaniasis. J Glob Infect Dis. 2010; 2(2):167-76. PMC: 2889657. DOI: 10.4103/0974-777X.62887. View
5.
Soto J, Valda-Rodriquez L, Toledo J, Vera-Navarro L, Luz M, Monasterios-Torrico H . Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg. 2004; 71(5):577-81. View